Michelle  Mcmurry-Heath net worth and biography

Michelle Mcmurry-Heath Biography and Net Worth

Director of Bioventus

Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO on June 1, 2020. A medical doctor and molecular immunologist by training, Dr. McMurry-Heath becomes just the third chief executive to steward the world’s largest biotechnology advocacy group since BIO’s founding in 1993.

BIO represents 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to support companies that discover and deploy scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture.

The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, McMurry-Heath calls “the distribution of scientific progress the social justice issue of our age.”

She comes to BIO from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. She was also instrumental in bringing J&J’s incubator, JLabs, to Washington, DC. She led a global team of 900 with responsibilities in 150 countries around the globe.

Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government. The Obama-Biden transition team tapped her to conduct a comprehensive analysis of the National Science Foundation’s policies, programs and personnel. President Obama then named her associate science director of the FDA’s Center for Devices and Radiological Health under Commissioner Peggy Hamburg. In that role, she championed clinical trial evolution, the use of real-world evidence in product evaluation, and an embrace of the patient’s voice in health research so new medical products deliver outcomes that matter to them.

McMurry-Heath was the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program, where she promoted personalized medicine and bolstered international preparation for pandemic disease threats. She received her early training in science policy from the Robert Wood Johnson Foundation and later served as Senator Joe Lieberman’s top legislative aide for science and health. In that role, she drafted legislation to protect the country from biological attacks.

McMurry-Heath received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African-American to graduate from the prestigious program. She spent 12 years working at the research bench before taking policy and leadership roles in government and industry.

McMurry-Heath lives in Washington, D.C. with her husband Sebastian Heath, a veterinarian, and their daughter, Isabella. To relax, she enjoys yoga, snorkeling and her daughter’s sporting events.

What is Michelle Mcmurry-Heath's net worth?

The estimated net worth of Michelle Mcmurry-Heath is at least $504.99 thousand as of November 7th, 2025. Mcmurry-Heath owns 56,997 shares of Bioventus stock worth more than $504,993 as of March 11th. This net worth evaluation does not reflect any other assets that Mcmurry-Heath may own. Learn More about Michelle Mcmurry-Heath's net worth.

How do I contact Michelle Mcmurry-Heath?

The corporate mailing address for Mcmurry-Heath and other Bioventus executives is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. Bioventus can also be reached via phone at 919-474-6700 and via email at [email protected]. Learn More on Michelle Mcmurry-Heath's contact information.

Has Michelle Mcmurry-Heath been buying or selling shares of Bioventus?

Michelle Mcmurry-Heath has not been actively trading shares of Bioventus over the course of the past ninety days. Most recently, Michelle Mcmurry-Heath sold 17,701 shares of the business's stock in a transaction on Friday, November 7th. The shares were sold at an average price of $7.42, for a transaction totalling $131,341.42. Following the completion of the sale, the director now directly owns 56,997 shares of the company's stock, valued at $422,917.74. Learn More on Michelle Mcmurry-Heath's trading history.

Who are Bioventus' active insiders?

Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Michelle Mcmurry-Heath (Director), Guy Nohra (Director), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.

Are insiders buying or selling shares of Bioventus?

In the last twelve months, insiders at the sold shares 6 times. They sold a total of 41,031 shares worth more than $322,332.14. The most recent insider tranaction occured on December, 4th when Director Guy P Nohra sold 10,000 shares worth more than $75,700.00. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.

Information on this page was last updated on 12/4/2025.

Michelle Mcmurry-Heath Insider Trading History at Bioventus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2025Sell17,701$7.42$131,341.4256,997View SEC Filing Icon  
See Full Table

Michelle Mcmurry-Heath Buying and Selling Activity at Bioventus

This chart shows Michelle Mcmurry-Heath's buying and selling at Bioventus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bioventus Company Overview

Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.86
Low: $8.63
High: $8.99

50 Day Range

MA: $8.17
Low: $7.21
High: $9.10

2 Week Range

Now: $8.86
Low: $5.81
High: $11.25

Volume

520,612 shs

Average Volume

292,089 shs

Market Capitalization

$733.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78